Skip to main content

Coenzyme Q10 and Heart Failure: A State-of-the-Art Review.

Publication ,  Journal Article
Sharma, A; Fonarow, GC; Butler, J; Ezekowitz, JA; Felker, GM
Published in: Circ Heart Fail
April 2016

Heart failure (HF) with either preserved or reduced ejection fraction is associated with increased morbidity and mortality. Evidence-based therapies are often limited by tolerability, hypotension, electrolyte disturbances, and renal dysfunction. Coenzyme Q10 (CoQ10) may represent a safe therapeutic option for patients with HF. CoQ10 is a highly lipophilic molecule with a chemical structure similar to vitamin K. Although being a common component of cellular membranes, CoQ10's most prominent role is to facilitate the production of adenosine triphosphate in the mitochondria by participating in redox reactions within the electron transport chain. Numerous trials during the past 30 years examining CoQ10 in patients with HF have been limited by small numbers and lack of contemporary HF therapies. The recent publication of the Q-SYMBIO randomized controlled trial demonstrated a reduction in major adverse cardiovascular events with CoQ10 supplementation in a contemporary HF population. Although having limitations, this study has renewed interest in evaluating CoQ10 supplementation in patients with HF. Current literature suggests that CoQ10 is relatively safe with few drug interactions and side effects. Furthermore, it is already widely available as an over-the-counter supplement. These findings warrant future adequately powered randomized controlled trials of CoQ10 supplementation in patients with HF. This state-of-the-art review summarizes the literature about the mechanisms, clinical data, and safety profile of CoQ10 supplementation in patients with HF.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Heart Fail

DOI

EISSN

1941-3297

Publication Date

April 2016

Volume

9

Issue

4

Start / End Page

e002639

Location

United States

Related Subject Headings

  • Ubiquinone
  • Treatment Outcome
  • Myocardium
  • Mitochondria, Heart
  • Humans
  • Heart Failure
  • Energy Metabolism
  • Drug Interactions
  • Dietary Supplements
  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sharma, A., Fonarow, G. C., Butler, J., Ezekowitz, J. A., & Felker, G. M. (2016). Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. Circ Heart Fail, 9(4), e002639. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002639
Sharma, Abhinav, Gregg C. Fonarow, Javed Butler, Justin A. Ezekowitz, and G Michael Felker. “Coenzyme Q10 and Heart Failure: A State-of-the-Art Review.Circ Heart Fail 9, no. 4 (April 2016): e002639. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002639.
Sharma A, Fonarow GC, Butler J, Ezekowitz JA, Felker GM. Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. Circ Heart Fail. 2016 Apr;9(4):e002639.
Sharma, Abhinav, et al. “Coenzyme Q10 and Heart Failure: A State-of-the-Art Review.Circ Heart Fail, vol. 9, no. 4, Apr. 2016, p. e002639. Pubmed, doi:10.1161/CIRCHEARTFAILURE.115.002639.
Sharma A, Fonarow GC, Butler J, Ezekowitz JA, Felker GM. Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. Circ Heart Fail. 2016 Apr;9(4):e002639.

Published In

Circ Heart Fail

DOI

EISSN

1941-3297

Publication Date

April 2016

Volume

9

Issue

4

Start / End Page

e002639

Location

United States

Related Subject Headings

  • Ubiquinone
  • Treatment Outcome
  • Myocardium
  • Mitochondria, Heart
  • Humans
  • Heart Failure
  • Energy Metabolism
  • Drug Interactions
  • Dietary Supplements
  • Cardiovascular System & Hematology